SCS System Shows Cost-Dominance Two Years Post-Implant

Image credit: Saluda Medical

New data published this month shows a strong case for the cost-effectiveness of Saluda Medical’s neuromodulation Evoke System for the treatment of chronic back and leg pain, when compared with open-loop spinal cord stimulation (SCS) devices.

Published last month in The Clinical Journal of Pain, the cost-unit analysis looked at the costs and outcomes of using the Evoke System over open-loop SCS when used to treat chronic back and leg pain, within the context of the United Kingdom’s National Health Services (NHS).

Researchers built an economic model to evaluate costs of each treatment based on published sources for expenses relating to devices, healthcare variables depending on patients’ response, and surgical removal of devices.

Results from the study indicate that the Evoke System was more cost effective than open-loop SCS after two years post-implantation, for “high responder” patients.

Closed-loop SCS devices respond in real-time to a patient and can automatically readjust programming as required, as opposed to conventional open-loop SCS devices which must be programmed and readjusted manually.

“We are committed to elevating SCS therapy with the best science, clinical, and health economic evidence, and the results from this study have set a new standard demonstrating cost-dominance of closed-loop therapy over open-loop therapy,” said Saluda Medical President and Chief Executive Officer, Jim Schuermann.

“In a market that has seen marginal innovation over recent years, this data is one more proof point on the transformational nature Evoke closed-loop therapy and its potential to drive the SCS market into the future.”

Check out the full statement from Saluda Medical for further details, or access the research article via The Clinical Journal of Pain.